Analyst Price Target is $33.00
▲ +266.67% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Enlivex Therapeutics in the last 3 months. The average price target is $33.00, with a high forecast of $33.00 and a low forecast of $33.00. The average price target represents a 266.67% upside from the last price of $9.00.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Enlivex Therapeutics.
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.